India Draws a Line on Self-Medication. The Kidneys Are the Reason.

NEW DELHI — India’s drug regulator has warned against the indiscriminate use of painkillers and antibiotics, highlighting risks including kidney damage and antimicrobial resistance.

The Central Drugs Standard Control Organisation issued the advisory on Monday under the authority of Drug Controller General Dr. Rajeev Singh Raghuvanshi. It addresses the entire medicine supply chain: patients, healthcare professionals, pharmacists, retailers, distributors, and hospital administrators.

The warning responds to a common pattern in India, where people can often purchase medicines such as ibuprofen without a prescription or meaningful screening for factors that increase risk, including older age, diabetes, or use of diuretics. The regulator’s intervention aims to make that routine transaction more cautious and accountable.

The kidney warning concerns a class of drugs called NSAIDs (non-steroidal anti-inflammatory drugs), which include ibuprofen, naproxen, aspirin, and diclofenac, all widely sold in India for pain and inflammation. Their mechanism in the kidney is specific. NSAIDs suppress the production of prostaglandins, fatty acid compounds that help regulate blood flow to the renal tissue. When prostaglandins are reduced, blood flow to the kidneys decreases. In a healthy person under ordinary conditions, the body compensates without incident. In someone who is dehydrated, elderly, or already living with reduced kidney function, or in someone taking a diuretic that compounds fluid loss, the body’s ability to compensate can fail. What results is acute kidney injury: sometimes reversible if caught early, sometimes accelerating toward permanent damage in those already vulnerable.

The stakes in India are not abstract. A 2023 study published in The Lancet estimated that 138 million adults in India live with chronic kidney disease, one of the highest absolute burdens in the world. A substantial proportion remain undiagnosed. Many take NSAIDs for pain, for inflammation, for the low-grade discomfort that formal healthcare never addresses because the clinic is too far, the fee unaffordable, or the problem seems too minor to justify the trip.

The antibiotic section of the advisory targets a different but related failure: self-medication for viral infections. Colds, fevers, and typical upper respiratory tract infections are overwhelmingly viral in origin. Antibiotics are ineffective against viruses. The habit of reaching for amoxicillin or azithromycin at the first sign of a fever, sold without a prescription across countless Indian pharmacies despite formal rules requiring one, has contributed directly to India’s antibiotic resistance burden. CDSCO’s circular cites the scale of the consequence: research on global antimicrobial resistance attributable mortality found 163,129 deaths linked to resistant Streptococcus pneumoniae in 2021, 142,310 to resistant E. coli, and 121,623 to Klebsiella pneumoniae, organisms that were once reliably treated with the same medicines now growing less effective.

CDSCO has engaged this problem before. India launched the Red Line campaign in 2016, placing a red line on antibiotic packaging to signal that a prescription was required. The National Action Plan on Antimicrobial Resistance followed in 2017. Both targeted the same gap: the distance between the formal requirement that antibiotics demand a prescription and the practical reality that they are routinely dispensed across retail pharmacies without one. According to the World Health Organization, antimicrobial resistance is now one of the top global public health and development threats, a problem India’s consumption patterns shape as much as any country.

What Monday’s circular does not announce is any new enforcement mechanism. It asks stakeholders, the same pharmacists, distributors, hospital management committees, and healthcare professionals named in the advisory, to comply with existing provisions of the Drugs and Cosmetics Act. Whether the gap between advisory language and dispensing practice narrows depends on pharmaceutical oversight at the last mile: the neighbourhood chemist, not the licensed distribution chain. That chemist already knows a prescription is technically required. The advisory does not change the economics that make asking for one inconvenient.

The CDSCO’s specific guidance on kidney risk is more practical. It asks that patients with existing kidney disease, heart failure, liver disease, diabetes, or hypertension be flagged before any NSAID is prescribed or dispensed. Dehydration, common across India year-round and severe through the summer months, is listed as a risk factor requiring clinical reconsideration before an NSAID is given. The combination of a diuretic with an NSAID creates a compounding effect on renal blood flow that the circular explicitly names. These are not new warnings for anyone with medical training; they are standards of care that the prescription system is designed to enforce and that over-the-counter access routinely bypasses.

India’s generic medicines manufacturing base is among the world’s most productive; the country generates roughly 20 percent of global generic pharmaceutical output by volume. That infrastructure creates access to effective medicines at prices most patients can reach. It also creates access without the gatekeeping that a functioning prescription system provides. The regulator’s advisory is a clear statement of the clinical problem. Whether it narrows the gap depends on enforcement capacity that the circular itself does not address.

What CDSCO cannot say, and did not say on Monday, is how many people in India are already paying the renal cost of that gap.